NCT02767479View on ClinicalTrials.gov

Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori

PHASE3CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

H. Pylori Infection

Interventions

DRUG

rabeprazole-based regimen

This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.

DRUG

esomeprazole^based regimen

This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.

Trial Locations (1)

431-3192

Hamamatsu University School of Medicine, Hamamatsu

All Listed Sponsors

lead

Hamamatsu University

OTHER

NCT02767479 - Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori | Biotech Hunter | Biotech Hunter